LAG3 and ovarian neoplasm: In a prophylactic MC38 ovarian tumor model treated with cemiplimab (anti-PD-1) and REGN3767 (anti-LAG-3), more mice were tumor-free, and tumor growth was significantly reduced on day 22, in the combination treatment group compared with the same-type control group (P < 0.05) and the REGN3767 group (P < 0.01) [47].